Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol investigation expands

Executive Summary

Investigation of Bristol-Myers Squibb by the New Jersey U.S. Attorney "has expanded to include a review of whether there was any violation of Federal securities laws in connection with the proposed settlement with Apotex" under the terms of a 2004 consent order with the Securities & Exchange Commission, the company says in its third quarter earnings release Oct. 26. The U.S. Attorney is investigating governance issues relating to the company's negotiations with Apotex; Bristol's failed settlement with Apotex over generic Plavix may impact the company's compliance with a deferred prosecution agreement with the New Jersey U.S. Attorney. The Department of Justice is also conducting a criminal investigation of the proposed settlement (1"The Pink Sheet" Aug. 14, 2006, p. 3)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS047722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel